1. Home
  2. XNET vs FHTX Comparison

XNET vs FHTX Comparison

Compare XNET & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$5.66

Market Cap

356.5M

Sector

Technology

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.38

Market Cap

360.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
FHTX
Founded
2003
2015
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
356.5M
360.8M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
XNET
FHTX
Price
$5.66
$5.38
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.67
AVG Volume (30 Days)
281.1K
163.7K
Earning Date
03-12-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
8740.73
N/A
EPS
20.16
N/A
Revenue
$401,918,000.00
$24,518,000.00
Revenue This Year
N/A
$40.91
Revenue Next Year
N/A
$11.87
P/E Ratio
$0.29
N/A
Revenue Growth
27.19
N/A
52 Week Low
$2.64
$2.95
52 Week High
$11.03
$6.95

Technical Indicators

Market Signals
Indicator
XNET
FHTX
Relative Strength Index (RSI) 32.72 47.24
Support Level $5.55 $5.11
Resistance Level $6.12 $5.74
Average True Range (ATR) 0.32 0.37
MACD -0.03 -0.06
Stochastic Oscillator 22.19 32.58

Price Performance

Historical Comparison
XNET
FHTX

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: